Skip to main content

Advertisement

Table 3 Serum POP related xenobiotic induced receptor transactivities in breast cancer patients and controls

From: Perfluorinated compounds are related to breast cancer risk in greenlandic inuit: A case control study

Parameters Cases Controls p value
  N (n) median 95% CI Min-max N(n) median 95% CI Min-max  
XER (RLU/μg protein) 31(31) 1.07 1.02; 1.10 0.80-1.30 115(110) 1.08 1.05; 1.11 0.54-1.34 0.69
   % agonistic XER   38.7%     32.7%    0.54
   % downregulated XER   9.7%     8.2%    0.79
XERcomp (RLU/μg protein) 31(31) 1.06 1.00; 1.08 0.79-1.27 115(110) 1.04 1.00; 1.05 0.55-1.26 0.58
   % additive XERcomp   22.6%     19.1%    0.67
   % antagonistic XERcomp   12.9%     12.7%    0.16
XAR (RLU/μg protein) 31(27) 1.02 0.97; 1.25 0.56-2.01 115(58) 0.91 0.86; 0.99 0.40-1.74 0.01
   % agonistic XAR   18.5%     5.17%    0.02
   % downregulated XAR   11.1%     24.1%    0.17
XARcomp (RLU/μg protein) 31(27) 0.69 0.61; 0.82 0.14-1.33 115(58) 0.72 0.68; 0.79 0.29-1.23 0.51
   % additive XARcomp   3.7%     0.0    0.14
   % antagonistic XARcomp   55. 6%     36.2%    0.59
AhR-TEQ (pg/L) 31(29) 292 285; 568 31.41-1442 115(113) 503 771; 1544 112-12757 <0.0001
AhR -TEQ (pg/g lipid) 31(29) 56.8 46.40; 90.80 8.97-231 115(113) 65.4 103; 219 11.50-2086 0.009
  1. N: total number of subjects, n: number of subjects having information for the corresponding parameters.
  2. XER and XAR: ER and AR transactivity of serum POP F1 extract alone, respectively. XERcomp and XARcomp: competitive receptor transactivity upon co-treatment with E2 or R1881, respectively. % agonistic XER and % XAR indicate a significant increase for the XER and XAR transactivity compared to the activity of the solvent control. % downregulated XER and % XAR indicated a significant decrease for the XER and XAR transactivity compared to the activity of the solvent control. % additive XERcomp and % additive XARcomp indicate a significant increase for the XERcomp and XARcomp transactivity compared to the activity of the E2-EC40 and R1881-EC50 solvent control, respectively. % antagonistic XERcomp and % antagonistic XARcomp indicate a significant decrease for the XERcomp and XARcomp transactivity compared to the activity of the E2-EC40 and R1881-EC50 solvent control, respectively. TEQ (TCDD equivalent): The TEQ value was calculated by interpolation of the AhR transactivity of serum extract to the TCDD dose-response curve using Sigmaplot program.